$VTVT
vTv Therapeutics Inc.

2018 Q1 Form 10-Q Financial Statement

#000156459018013639 Filed on May 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $2.064M $30.00K
YoY Change 6780.0% -92.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.260M $2.820M
YoY Change -19.86% 9.3%
% of Gross Profit
Research & Development $8.940M $10.96M
YoY Change -18.43% -1.62%
% of Gross Profit
Depreciation & Amortization $42.00K $52.00K
YoY Change -19.23% -34.18%
% of Gross Profit
Operating Expenses $11.20M $13.78M
YoY Change -18.75% -0.95%
Operating Profit -$9.134M -$13.75M
YoY Change -33.59% 1.58%
Interest Expense -$840.0K $559.0K
YoY Change -250.27% 27850.0%
% of Operating Profit
Other Income/Expense, Net $10.00K $0.00
YoY Change -100.0%
Pretax Income -$9.960M -$14.29M
YoY Change -30.28% 5.67%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.952M -$4.220M
YoY Change -30.05% 9.55%
Net Earnings / Revenue -143.02% -14066.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$304.1K -$435.5K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.500M $45.20M
YoY Change -85.62% -40.13%
Cash & Equivalents $9.035M $45.15M
Short-Term Investments
Other Short-Term Assets $2.800M $800.0K
YoY Change 250.0% -38.46%
Inventory
Prepaid Expenses
Receivables $200.0K $0.00
Other Receivables $0.00
Total Short-Term Assets $9.500M $45.90M
YoY Change -79.3% -40.47%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $400.0K
YoY Change -50.0% -20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.500M
YoY Change
Other Assets $2.500M $2.000M
YoY Change 25.0% 5.26%
Total Long-Term Assets $5.200M $2.400M
YoY Change 116.67% -4.0%
TOTAL ASSETS
Total Short-Term Assets $9.500M $45.90M
Total Long-Term Assets $5.200M $2.400M
Total Assets $14.70M $48.30M
YoY Change -69.57% -39.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.30M $11.10M
YoY Change 1.8% 29.07%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $6.800M
YoY Change
Total Short-Term Liabilities $26.80M $11.10M
YoY Change 141.44% 27.59%
LONG-TERM LIABILITIES
Long-Term Debt $13.10M $18.80M
YoY Change -30.32%
Other Long-Term Liabilities $3.200M $300.0K
YoY Change 966.67% 50.0%
Total Long-Term Liabilities $16.30M $19.10M
YoY Change -14.66% 9450.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.80M $11.10M
Total Long-Term Liabilities $16.30M $19.10M
Total Liabilities $163.5M $171.8M
YoY Change -4.83% 20.48%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$148.8M -$123.5M
YoY Change
Total Liabilities & Shareholders Equity $14.70M $48.30M
YoY Change -69.57% -39.32%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$2.952M -$4.220M
YoY Change -30.05% 9.55%
Depreciation, Depletion And Amortization $42.00K $52.00K
YoY Change -19.23% -34.18%
Cash From Operating Activities -$5.397M -$13.82M
YoY Change -60.95% 10.56%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $39.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $10.00K $0.00
YoY Change
Cash From Investing Activities $12.00K -$40.00K
YoY Change -130.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 7.500M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.397M -13.82M
Cash From Investing Activities 12.00K -40.00K
Cash From Financing Activities 0.000 7.500M
Net Change In Cash -5.385M -6.360M
YoY Change -15.33% -49.12%
FREE CASH FLOW
Cash From Operating Activities -$5.397M -$13.82M
Capital Expenditures $0.00 $39.00K
Free Cash Flow -$5.397M -$13.86M
YoY Change -61.06% 10.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2436000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4497000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
681000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
413000
CY2017Q4 us-gaap Notes Payable
NotesPayable
19587000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
963000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
739000
CY2018Q1 us-gaap Sales Revenue Net
SalesRevenueNet
2064000
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
30000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10960000
CY2018Q1 vtvt Other Income Expenses Related Party
OtherIncomeExpensesRelatedParty
-25000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9960000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-9960000
CY2017Q1 us-gaap Profit Loss
ProfitLoss
-14286000
CY2018Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7008000
CY2017Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-10066000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2952000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-4220000
CY2018Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
213000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
963000
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
151000
CY2018Q1 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
3884000
CY2018Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
12000
CY2017Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-5000
CY2018Q1 us-gaap Depreciation
Depreciation
42000
CY2017Q1 us-gaap Depreciation
Depreciation
52000
CY2018Q1 vtvt Change In Fair Value Of Warrants Related Party
ChangeInFairValueOfWarrantsRelatedParty
25000
CY2018Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
275000
CY2017Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
203000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7790000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2072000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13816000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
170000
CY2018Q1 vtvt Increase Decrease In Long Term Deposits
IncreaseDecreaseInLongTermDeposits
-2256000
CY2017Q1 vtvt Increase Decrease In Long Term Deposits
IncreaseDecreaseInLongTermDeposits
37000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2605000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-308000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2064000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-17000
CY2018Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-35000
CY2017Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
3000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5397000
CY2018Q1 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
12000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
12000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-39000
CY2017Q1 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
7500000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7500000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5385000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6355000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14420000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51505000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9035000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45150000
CY2018Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
151000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25224933
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A Common Stock, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of derivative liabilities, and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</p></div>
CY2018Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounts receivable balances outstanding as of March&#160;31, 2018 consisted of milestone payments receivable related to the Company&#8217;s agreement with JDRF International (&#8220;JDRF&#8221;).&nbsp;&nbsp;The accounts receivable balance at December 31, 2017 related to an upfront payment received in the first quarter of 2018 pursuant to the Company&#8217;s license agreement with <font style="color:#000000;">Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (&#8220;Huadong&#8221;)</font>.&nbsp;&nbsp;</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two and one customers represented 100% of the revenue earned during the three months ended March&#160;31, 2018 and 2017, respectively. </p></div>
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.43
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
8.53
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
963000
CY2018Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2018Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
138000
CY2018Q1 us-gaap Notes Payable
NotesPayable
19862000
CY2018Q1 vtvt Redeemable Noncontrolling Interest Temporary Equity Redemption Value
RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
120400000
CY2017Q4 vtvt Redeemable Noncontrolling Interest Temporary Equity Redemption Value
RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
131400000
CY2018Q1 us-gaap Deferred Revenue
DeferredRevenue
11190000
CY2017Q4 us-gaap Deferred Revenue
DeferredRevenue
13254000
CY2018Q1 vtvt Increase Decrease In Deferred Revenue Current
IncreaseDecreaseInDeferredRevenueCurrent
-3000
CY2018Q1 vtvt Increase Decrease In Deferred Revenue Noncurrent
IncreaseDecreaseInDeferredRevenueNoncurrent
-2061000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7115
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0269
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1960732
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
30000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1990732
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1006917
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1946782
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y2M12D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.50
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.85
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.48
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27780245

Files In Submission

Name View Source Status
0001564590-18-013639-index-headers.html Edgar Link pending
0001564590-18-013639-index.html Edgar Link pending
0001564590-18-013639.txt Edgar Link pending
0001564590-18-013639-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201805141437262594275.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtvt-10q_20180331.htm Edgar Link pending
vtvt-20180331.xml Edgar Link completed
vtvt-20180331.xsd Edgar Link pending
vtvt-20180331_cal.xml Edgar Link unprocessable
vtvt-20180331_def.xml Edgar Link unprocessable
vtvt-20180331_lab.xml Edgar Link unprocessable
vtvt-20180331_pre.xml Edgar Link unprocessable
vtvt-ex311_9.htm Edgar Link pending
vtvt-ex312_6.htm Edgar Link pending
vtvt-ex321_8.htm Edgar Link pending
vtvt-ex322_7.htm Edgar Link pending